COCP — Cocrystal Pharma Share News
0.000.00%
Last trade - 00:00Cocrystal Pharma Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Cocrystal Pharma Engages Cro To Conduct Phase 2A Human Challenge Influenza A Clinical Trial With Candidate CC-42344
Brief: Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data In Influenza A Once-Daily Dosing
Cocrystal Pharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Cocrystal Pharma Reports First Quarter 2022 Financial Results
Brief: Cocrystal Pharma Collaborates With National Institute Of Allergy And Infectious Diseases
Brief: Cocrystal Pharma Reports Favorable Prelim Data From Phase 1 Initial Cohorts With CC-42344
Cocrystal Pharma Inc reports results for the quarter ended in December - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 4 cents a share - Earnings Preview
Cocrystal Pharma rises on starting influenza treatment safety trial
Brief: Cocrystal Pharma Initiates Enrollment In Phase 1 Influenza A Study With Novel, Broad-Spectrum, Orally Administrated Antiviral Cc-42344
Brief: Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates For Its Covid-19 Oral Drug Program
Brief: Cocrystal Pharma Receives FDA Guidance To Advance Clinical Development Of Its COVID-19 Antiviral CDI-45205
Diagnostics, Williams-Sonoma, Cytokinetics
U.S. STOCKS ON THE MOVE-Vaccine makers, SeaChange, Voya Financial, BiondVax
U.S. STOCKS ON THE MOVE-Reliance Global, Allakos, Acasti Pharma, CalAmp Corp
Cocrystal Pharma jumps as antivirals effective against Omicron in lab studies
Brief: Cocrystal Pharma’s Covid-19 Oral, Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against The Sars-Cov-2 Omicron Variant
Brief: Cocrystal Pharma Presents Preclinical Data From Covid-19 Antiviral Programs